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ABSTRACT: Local delivery of bioactive molecules to the inner ear via diffusion through the round window membrane is
becoming an attractive approach to treat sensorineural hearing loss compared to systemic drug administration. Pluronics R© (Lutrol
F127) are a class of thermosensitive hydrogels that remain liquid prior to injection and rapidly gel under physiological conditions.
They are, however, limited to short-term drug release due to rapid hydrolysis in aqueous solution. Therefore, the aim of this study
was to investigate an approach, using an ink-jet printing system, to sustain the drug release by incorporating hydrogel microspheres
within Lutrol F127. Various concentrations of Lutrol F127 and calcium chloride (CaCl2) were examined by rheology to determine the
optimum combinations to use for injection and then blended with inkjet-printed alginate microspheres. Drug release (FITC-Dextran)
from Lutrol F127 alone reached completion in less than 24 h. Release from alginate spheres alone showed a burst release and reached
100% in 6 h. Interestingly, the incorporation of microspheres within Lutrol F127 allowed a more sustained release profile and a slower
burst release. By varying the quantity of microspheres, concentration of alginate, or ionic cross-linking ratio, the release profile can be
adjusted to suit the desired application. C© 2015 Wiley Periodicals, Inc. Adv Polym Technol 2016, , 21571; View this article online at
wileyonlinelibrary.com. DOI 10.1002/adv.21571
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Introduction
S ensorineural hearing loss results from damage at any pointbetween the cochlea hair cells and the auditory cortex in
the brain, most commonly at the hair cells.1 As neurons and
hair cells in humans do not regenerate spontaneously, major-
ity of treatment options were more focused toward functional
improvements (i.e., hearing aids and cochlear implants) rather
than a medical treatment.2,3 However, local delivery of bioactive
molecules intratympanically (diffusion across the round win-
dow membrane) is becoming a major approach to protecting
the neurosensory structures of the inner ear after injury, as con-
ventional systemic drug administration may be less effective
due to physiological and anatomical barriers such as the blood–
cochlea barrier that limit drug levels within the inner ear.4–7
Local therapy to the inner ear is also ideally suited to the admin-
istration of therapeutics that may be toxic when administered
systemically, and in this regard trophic agents or antiapoptotic
agents are under investigation.
Using injectable hydrogels to deliver bioactive molecules
have become an attractive method compared to traditional im-
plantable drug delivery systems as these minimize surgical
intervention and mostly can be prepared simply via physi-
cal mixing. Injectable hydrogels can be formed in situ by ei-
ther chemical polymerization or sol–gel phase transition. The
sol–gel transition systems remain liquid prior to injection, but
rapidly gel under physiological conditions.8 This means that
these materials can adapt to any shape within the target site
and provide a uniform distribution of bioactive molecules at
the injection site once gelled. Pluronics R© (Lutrol F127) are
a class of commercially available thermosensitive hydrogels
that have been widely reported as injectable hydrogels in tis-
sue engineering applications.9 At moderate concentrations (15–
30% w/w), these triblock copolymers of poly(ethylene oxide)–
poly(propylene oxide)–poly(ethylene oxide) (PEO–PPO–PEO)
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FIGURE 1. Schematic diagram of sol–gel transition of Lutrol F127 aqueous solution upon reaching a critical concentration and temperature.
undergo a reversible thermal transition in aqueous solution un-
der physiological temperature and pH, as shown in Fig. 1.10,11
However, the major drawback of the system is the rapid erosion
of the gel by body fluids, thereby limiting its long-term drug
release.12 Attempts to prolong drug release can include additives
or blending of polymers,13,14 changing size or hydrophobicity of
the drug to be released,15 or via the addition of a second drug
carrier system.11,16 Here, we will adapt on the later approach by
using a nozzle-based ink-jetting system to fabricate alginate mi-
crospheres that will act as a secondary drug carrier system once
embedded within Lutrol F127.
Nozzle-based ink-jetting system has been long favored in the
fabrication of microspheres due to its good size distribution,
controllability, and scale-up potential.17,18 On the other hand, al-
ginate is known for its cell compatibility and good stability.19
Therefore, the objective of this study was to evaluate the feasi-
bility of incorporating alginate hydrogel microspheres into the
thermosensitive gel (Lutrol F127) for sustained intratympanic
delivery of FITC-dextran as the model drug. In addition, the use
of inkjet printing as a simple and alternative method to fabricate
hydrogel microspheres will be assessed.
Materials and Methods
MATERIALS
Poloxamer 407 (Lutrol F127), alginic acid sodium salt (vis-
cosity of 100–300 cP for 2 wt% solution, 25°C), and model drug
(FITC-dextran 20 kDa) were obtained from Sigma-Aldrich, Aus-
tralia. Other reagents were all analytical grade and used as re-
ceived.
LUTROL F127 INK FORMULATION
Lutrol F127 solutions (% w/v) were prepared in saline (0.9%
NaCl) using the cold method.20 In brief, appropriate quantities
of Lutrol F127 were slowly added to a cold buffer solution and
stirred until a clear, homogeneous liquid formed. The gel for-
mulations were kept under refrigeration (4°C) and thoroughly
stirred before experiments.
FABRICATION OF ALGINATE MICROSPHERES
USING INKJET PRINTING SYSTEM
Printing was conducted using a piezoelectric Dimatix Ma-
terials Printer 2800 (DMP 2800m; Fujifilm, Santa Clara, CA),
equipped with a 16 nozzle 10 pL cartridge (DMCLCP-11610) at
a drop spacing of 50 μm and height from 18 mm. Alginate solu-
tion at 0.5% w/v was printed into a cross-linking bath of 1, 2, or
5% w/v CaCl2 to determine the optimum concentration of cross-
linking concentration to obtain consistent hydrogel spheres. The
printed alginate microspheres were imaged using a Leica DMIL
LED microscope (Leica Microsystems, Wetzlar, Germany) and




A schematic diagram of the preparation process is shown
in Fig. 2. In brief, alginate (0.5% w/v) in saline (0.9% NaCl)
was loaded into the cartridge and printed into a cross-linking
solution of 2% w/v CaCl2 and 10 μg/mL FITC-dextran. A total
of 100,000 or 500,000 microspheres/mL were printed into the
cross-linking solution. The solution was kept away from light
for 1 day for the alginate microspheres to reach equilibrium.
From the solution, appropriate amounts of Lutrol F127 were
added to obtain a final concentration of 20% w/v Lutrol F127,
FIGURE 2. Schematic diagram of preparing the microsphere-loaded
injectable delivery system.
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0.5% w/v CaCl2, and 2 μg/mL drug loading. This concentration
was used based on a series of experiments and discussed in
Sections Rheology and Microsphere Fabrication. A final drug
loading of 2 μg/mL was selected based on the standard curve
conducted (not shown) showing that this loading would fit well
within the detection limit of the instrument.
RHEOLOGY
The rheological behavior of Lutrol F127 formulations was an-
alyzed using an AR-G2 rheometer (TA Instruments, New Castle,
DE) equipped with a Peltier plate thermal controller. A 2º/40 mm
cone and plate geometry was used in all measurements. The so-
lutions were allowed to reach the equilibrium temperature for 1
min prior to performing the experiments.
Storage modulus (G′) and loss modulus (G′ ′) were measured
as a function of temperature (at a constant frequency). Temper-
ature sweep experiments were conducted at a rate of 2ºC/min
from 7 to 70ºC at a fixed strain and frequency of 1% and 1 Hz, re-
spectively. Viscosity was measured as a function of temperature
at a constant shear rate. Temperature ramp experiments were
conducted at a ramp rate of 1ºC/min from 5 to 70ºC at a shear
rate of 1/s.
IN VITRO DRUG RELEASE STUDY
Drug release studies for Lutrol F127 and its formulations with
microspheres were conducted using a membrane-less method
in saline at 37ºC. Materials (1 mL) were cast directly into
preweighed glass vials of 1 cm inner diameter. Glass vials were
kept in a 37°C incubator until the material has gelled. The ini-
tial weight of samples was recorded and a sink volume of 1 mL
saline was added to the vials and placed in an incubator on an
orbital shaker at 60 rpm. At regular time intervals, the release
medium was temporarily removed and small aliquots (200 μL)
were taken to be measured by a fluorescent reader (FLUOstar
Omega, Offenburg, Germany). The weight of the glass vial and
gel was recorded to calculate the mass loss of the gel and the re-
lease medium was then added back into the vials. The readings
were taking at an excitation wavelength of 490 nm and emission
of 520 nm. The assay was repeated in triplicate and each assay
consisted of a triplicate of each material.
For drug release from microspheres, appropriate amounts of
alginate and the model drug were prepared in saline and loaded
into the printer cartridge. These were calculated to yield the
same total drug loading as Lutrol F127 and Lutrol F127 micro-
spheres. CaCl2 cross-linking solution was placed beneath the
inkjet cartridge. Printed microspheres were immediately trans-
ferred into glass vials and drug release was conducted similarly
as mentioned above.
DRUG RELEASE KINETICS AND MECHANISM STUDY
Release kinetics were evaluated according to the following
models: zero-order kinetics (Eq. (1)), first-order kinetics (Eq. (2)),
and Higuchi’s square root of time (Eq. (3)).11,21
M = k0t (1)




where M is the cumulative amount of drug release, Mt is the
amount of drug released in time t, M0 is the initial amount of
drug in the material, and k0, k1, and kH are, respectively, the zero-
order, the first-order, and the Higuchi’s release constant. The
drug release mechanism was studied using the semiempirical
Peppas model (Eq. (4)).22
Mt/M0 = K tn (4)
where Mt is the amount of drug released in time t, M0 is the initial
amount of drug in the material, K is the kinetic constant, and n is
the release exponent. The equation was applied to the first 60% of
fractional release. For a cylindrical system, n = 0.45 corresponds
to Fickian diffusion (diffusion controlled), n = 0.89 corresponds
to non-Fickian (Case II transport), and values between 0.4 and
0.89 are referred to as anomalous transport.
Results
RHEOLOGY
The thermosensitive hydrogel, Lutrol F127 (copolymers of
PEO–PPO–PEO), responds to both temperature and concentra-
tion changes. Therefore, the flow properties of Lutrol F127 as a
function of temperature were assessed using rheology (Fig. 3a).
At low temperatures, the formulation showed a typical fluid-like
behavior, as indicated by the higher loss modulus than storage
modulus (G′ > G′). As temperature increases, both the storage
modulus (G′) and loss modulus (G′′) increases rapidly and the
gelation temperature (where G′ and G′′ cross over) for 20% (w/v)
Lutrol F127 occurs around room temperature (RT25ºC). The G′,
however, stays below G′′ after the transition temperature, indi-
cating that the material did not exhibit characteristics of a true
gel. Figure 3b compares the transition temperature of Lutrol F127
against concentration. For ease of interpretation, only the storage
modulus (G′) is presented here. Clearly, the transition temper-
ature shifts to lower temperature with increasing Lutrol F127
concentration with the 30% w/v formulation gelling at around
15°C. On the other hand, 15% w/v Lutrol F127 simply behaved
as a free flowing fluid, where G′ remained low across all temper-
atures. As the purpose of an injectable drug delivery system in
this case is to inject in the form of a liquid at room temperature
that would gain strength in vivo, formulations of around 20%
w/v were more suitable for this scenario.
Cross-linking of alginate microspheres requires the use of
CaCl2, therefore the behavior of Lutrol F127 with CaCl2 was ex-
amined by rheology and is shown in Fig. 4. In this case, a sudden
increase in viscosity at a certain temperature would be indica-
tive of the transition temperature of Lutrol F127 from solution
to gel. The measurements showed that the presence of calcium
ions in the solution shifts the transition temperature to lower
temperatures along with an increase in viscosity. Formulation
with the least amount of calcium ions was selected for further
21571 (3 of 8)
RESEARCH ARTICLE
FIGURE 3. Rheological measurements. (A) Temperature sweep
measurements of an aqueous solution of 20% (w/v) Lutrol F127.
Transition temperature indicated by the temperature where G′
intersects G′ ′. (B) Temperature sweep measurements comparing
various concentrations of Lutrol F127. Only the storage modulus (G′)
was indicated for ease of interpretation.
investigation by varying the concentration of Lutrol F127, as
shown in Fig. 5. The formulation with 20% w/v Lutrol F127 +
0.5% w/v CaCl2 was found to have a viscosity higher than other
concentrations at body temperature (37°C), while still having
a transition temperature of 25°C. Therefore, this Lutrol F127
and CaCl2 combination were selected to be the most suitable
concentration for injection.
MICROSPHERE FABRICATION
Alginate (0.5% w/v) solution was printed via inkjet into a
cross-linking bath of 1, 2, or 5% w/v CaCl2 to determine the op-
timum concentration for cross-linking as shown in Fig. 6. Images
of microspheres cross-linked in 2% w/v and 5% w/v CaCl2 bath
were more circular and smaller as compared to spheres in 1%
w/v CaCl2. Analysis of the sphere diameter was converted into
a frequency distribution histogram and showed that increas-
ing cross-linking concentration leads to smaller average sphere
diameters and consistency (diameter decreases from 37.9 to 12.2
μm for 1% w/v and 5% w/v CaCl2, respectively). Lower dis-
persion across the histogram indicated that the microspheres in
higher concentration baths were more consistent in size. Based
on these observations, the 2% w/v CaCl2 was identified to
be the minimum cross-linking concentration required for this
inkjet printing setup to obtain microspheres with narrow size
distribution.
IN VITRO DRUG RELEASE STUDIES
The cumulative release and mass loss profile of 20% w/v
Lutrol F127 are shown in Fig. 7. In 24 h, the release of the model
drug (FITC-dextran) reached completion and the percentage ma-
terial remaining was 10%. This showed that the material is sus-
ceptible to hydrolysis and the drug release is not only via mecha-
nisms of diffusion, but also through erosion. The release kinetics
of samples was evaluated using the zero-order, first-order, and
Higuchi’s equations as shown in Table I. The coefficient of de-
termination (r2) for each sample is displayed in the table with
the r2 closest to unity underlined. The highest r2 values for all
samples were in the Higuchi’s model, indicating that the release
of the model from all system was a diffusion-dependent pro-
cess. Based on the power law equation, the values of n were
FIGURE 4. Temperature ramp measurements of 20% (w/v) Lutrol
F127 with various amounts of CaCl2 added.
FIGURE 5. Temperature ramp measurements with various
concentration of Lutrol F127 added to 0.5% (w/v) CaCl2.
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FIGURE 6. Images of alginate microspheres printed in cross-linking baths of 1, 2, 5% (w/v) CaCl2 (A–C). Frequency distribution histograms of 0.5%
(w/v) in various CaCl2 baths (D–F).
FIGURE 7. Cumulative release profile of 20% (w/v) Lutrol F127




Zero Order First Order Higuchi Peppas
System r2 r2 r2 n
Lutrol F127 0.570 0.407 0.968 0.693








0.887 0.505 0.977 0.608
all between 0.45 and 0.89 (n = 0.693 for pristine Lutrol F127,
n = 0.626 and 0.608 for Lutrol F127 loaded with 100,000 and
500,000 microspheres/mL, respectively), indicating that the re-
lease mechanism was a combination of Fickian diffusion and
Case II transport. This suggested that the drug not only diffuses
through the polymer matrix but also through the material erod-
ing. The model was not applied for the release profile of alginate
microspheres as the burst release was greater than 60% within
the first 30 min.
For drug release of alginate microspheres, the release reached
completion in 6 h along with a very large burst effect, as shown
in Fig. 8. This suggested that the drug release has already taken
place the moment the spheres came in contact with the cross-
linking solution after ejection. In comparison, by printing mi-
crospheres into a cross-linking solution containing the drug fol-
lowed by the addition of Lutrol F127, the release profile became
more sustained. Incorporating 100,000 microspheres/mL into
Lutrol F127 showed a lower burst effect in the first 30 min and
released only 45% as compared to 94% for spheres without be-
ing embedded inside Lutrol F127. The release profile of Lutrol
F127 with microspheres was also more sustained than pristine
Lutrol F127 (Fig. 7) and released only 70% in 24 h. By increasing
the number of microspheres within Lutrol F127 to 500,000 mi-
crospheres/mL while keeping the total mass of drug per sample
unchanged (2 μg/mL), the amount of drug released at every
time point was further reduced. The release from Lutrol F127
with 100,000 microspheres/mL was around 70% and 80% after 1
and 5 days, respectively, whereas Lutrol F127 with 500,000 micro-
spheres/mL released around 63% and 75% after 1 and 5 days, re-
spectively. While no significant difference was observed between
release profiles of Lutrol F127 with 100,000 microspheres/mL
and Lutrol F127 with 500,000 microspheres/mL, in both cases
21571 (5 of 8)
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FIGURE 8. Cumulative release profiles of alginate microspheres
incorporated with model drugs in saline (100,000 microspheres only)
and dispersed in 20% (w/v) Lutrol F127 (n = 3). Data represents mean
± SD.
the release was considerably prolonged compared to beads only
and Lutrol F127 only cases.
Discussion
Injectable hydrogels have become an attractive approach to
delivery drugs locally as compared to traditional implantable
drug delivery systems. The combination of microspheres and
injectable hydrogels can result in a prolonged drug release pro-
file not seen when these systems are used individually. With the
addition of using an inkjet printing system to fabricate micro-
spheres, the steps to prepare an injectable system with micro-
sphere carriers can be largely reduced. This is in comparison
to common procedures, where the fabrication of drug carrying
carriers and the matrix polymer were prepared separately in
multiple steps. 13,16,23
Lutrol F127 was selected as the drug carrier for injectable ap-
plications due to its reversible sol–gel transition behavior and
ability to incorporate both hydrophilic and hydrophobic sub-
stances that are insoluble in aqueous solution. It is well doc-
umented in the literature that both micellization and gelation
depend on different factors, namely, temperature and polymer
concentration.24 This is consistent with the observation from rhe-
ological measurements that an increase in polymer concentra-
tion leads to an increase in viscosity but also a lowering of gela-
tion temperature.
Prior to reaching the critical micellar concentration (CMC),
Lutrol F127 exists as individually monomolecular micelles at
low concentrations. As the concentration increases, a phase tran-
sition from a free-flowing solution to a gel-like structure occurs
at a certain temperature, referred to as the critical micellar tem-
perature (CMT). This was clearly observed when comparing be-
tween 15% w/v Lutrol F127 and samples greater than 20% w/v.
The 15% w/v Lutrol F127 did not show a substantial increase
in storage modulus across the range of temperatures tested as it
did not reach the CMC necessary to induce aggregation at higher
temperatures. Lutrol F127, however, did not exhibit a “true gel”
behavior as indicated by the lower G′ than G′ ′ beyond the tran-
sition temperature. It has been reported that the formation of
gel-like characteristics was due to the progressive dehydration
of the PPO core and formation of multimolecular clusters with
the hydrophilic PEO facing outwards.10,11 Therefore, it is possi-
ble that the aggregation of micelles could increase the viscosity,
allowing it to behave like a gel but is still not indicative of a “true
gel.” In addition, it is necessary to note that the increase in poly-
mer concentration also results in a reduction of CMT, which can
lead to difficulty in handling at room temperature. Therefore,
the 20% w/v Lutrol F127 was selected as the concentration for
further characterization.
To fabricate alginate microspheres, a cross-linking solution
is usually required. Therefore, it was necessary to examine the
effect of ions on the gelation temperature of Lutrol F127, as the
microspheres in the cross-linking solution will be combined with
Lutrol F127. The addition of divalent cations, in this case CaCl2,
shifted the transition temperature of Lutrol F127 to lower tem-
peratures. The lowering of transition temperature was propor-
tional to the increase in calcium concentration. Studies into the
effects of various salts on the transition temperature of F127 have
been conducted by Pandit et al.25,26 The lowering of transition
temperature can be explained by the dehydration of the PPO
block, lowering the solubility and favoring micellization.25 As
a result, both the CMC and CMT will be lowered since a gel
containing these salts at any given temperature will consist of
micelles that are more closely packed than gels without salt.26
Fabrication of alginate microspheres using a nozzle-based
ink-jetting system enables the production of uniform drop sizes
with good control, which otherwise can affect the reliability of
drug release results from inconsistent particle size. Sodium al-
ginate was selected as the microsphere matrix material in this
study for its ease of gelation, mechanical stability, and good tis-
sue compatibility.19 The printing of alginate microspheres into
various concentrations of CaCl2 indicated that the use of higher
concentration baths leads to smaller and more circular beads.
This is consistent with the literature where the generation of
particles improves with CaCl2 concentration.18 In this study, a
lower alginate concentration (0.5% w/v) was used as compared
to studies also printing alginate. This was due to the higher
chances of clogging at the nozzle when higher concentrations
(>0.5% w/v) were used. In addition, studies printing with con-
centrations greater than 1% w/v use either a nozzle size much
larger than the cartridge used in this study (21 μm),18 or by
adapting a commercial inkjet system that can eject high viscous
solution up to 100 mPa/s.27 Combining this result with the pre-
vious findings on Lutrol F127 and CaCl2 concentrations, the 2%
w/v CaCl2 bath was found to be the minimal concentration for
printing and was diluted with Lutrol F127 to yield a final con-
centration of 20% w/v Lutrol F127 + 0.5% w/v CaCl2 for drug
delivery.
The in vitro drug release of FITC-dextran from 20% w/v
Lutrol F127 reached completion in 24 h, along with a continu-
ous decrease in polymer mass at each measured time point. This
indicated that release of drugs from Lutrol F127 was not only
through the mechanism of diffusion but also through erosion
of the polymer matrix.11,28 A method to sustain the release was
through the addition of microspheres within the drug contain-
ing polymer matrix. It was observed that the incorporation of
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microspheres into Lutrol F127 has decreased not only the burst
release, but further sustained the total release compared to pris-
tine Lutrol F127 and drug-loaded microspheres alone. This is
consistent with studies in the literature where the incorporation
of drug-loaded microparticles/nanoparticles in polymer matri-
ces has decreased the burst effect compared to their individual
counterparts.23 The drug loading capacity for this system was
selected after considering the solubility and detection limit of
FITC-dextran and can be simply increased or decreased depend-
ing on the required therapeutic window and drug solubility.
By combining the two components together, Lutrol F127 can
act as an additional diffusion pathway for the drugs in the micro-
spheres and drug release can be further sustained. In addition,
since both Lutrol F127 and alginate microspheres now contain
drugs, the concentration gradient between these two will be-
come smaller, allowing the release of drugs from microspheres
to be also dependent on the dissolution of Lutrol F127. A similar
concept was reported by Giovagnoli et al.,16 where the release
of doxycycline from alginate microparticles embedded in F127
was 80% in 3 days. Their system however was added with a
thickening agent to further increase the stability of Lutrol F127
and only benefited the release profile during earlier time points.
By adapting a nozzle-based ink jetting system to fabricate micro-
spheres, this injectable formulation can be subjected to simple
adjustments, such as sphere quantity, size, cross-linking solu-
tion, and concentration of hydrogel. These have the potential
to alter the release profile as seen by the release profile when
microsphere quantity was increased from 100,000 to 500,000 mi-
crospheres/mL.
It is also noteworthy that the current drug release setup may
not accurately represent the conditions in the middle ear. Stud-
ies conducted by Wang et al.5,6 have reported longer release
times using pristine 17% Lutrol F127, where the polymer de-
livered dexamethasone up to 10 days when injected intratym-
panically. The in vitro release studies were, however, conducted
on snapwells consisting of a 0.4 μm pore polycarbonate mem-
brane. Within the middle ear, Lutrol F127 will not be in direct
contact with the perilymph (with diffusion through round win-
dow membrane, and also the stapes as has recently been demon-
strated by O’leary and co-workers).29,30 Therefore, the concen-
tration gradient will be lower and the dissolution of the polymer
will be lower too. In addition, as the perilymph effectively does
not flow, which is a very different situation to the rotating fluid
on an orbital shaker, it is believed that the current system when
injected in vivo could be more sustained.31 Further studies will
be conducted using a Franz-type diffusion cells that is often used
to study drug release through skin.32–34 Collectively, this work
has identified that 20% w/v Lutrol F127 with 0.5% w/v CaCl2
formulations with alginate microspheres provides an excellent
substrate for injectable drug delivery purposes, while maintain-
ing processability and can be easily modified to alter the drug
release profile.
Conclusions
An injectable drug delivery system for the middle ear was ex-
plored by embedding alginate microspheres into a thermosensi-
tive gel, Lutrol F127. In addition, a nozzle-based printing system
was assessed as an alternative method to fabricate hydrogel mi-
crospheres that can largely simply be the formulation process
of the injectable delivery system. The optimum combinations of
polymer and cross-linking conditions of each component were
determined by rheology and microscopy. In vitro drug release
of a model drug (FITC-dextran) from pristine Lutrol F127 and
alginate microspheres both reached completion in less than 24
h. Interestingly, the incorporation of microspheres within Lutrol
F127 showed sustained release and a lower burst effect due to
the presence of a secondary barrier to diffusion and a lower con-
centration gradient. The profile is likely to be further sustained
in vivo due to the less extreme sink conditions and future stud-
ies will first look into experimenting with a Franz-type diffusion
cell setup. The approach presented in this study demonstrated a
simple route to formulate injectable hydrogel-containing micro-
spheres, where the release profile can be altered easily through
changes in printing parameters and condition.
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10. Escobar-Chávez, J. J.; López-Cervantes, M.; Naı̈k, A.; Kalia, Y. N.; Quintanar-
Guerrero, D.; Ganem-Quintanar, A. J Pharm Pharm Sci 2006, 9(3),
339–358.
11. Nie, S.; Hsiao, W. L.; Pan, W.; Yang, Z. Int J Nanomed 2011, 6, 151–166.
12. Lippens, E.; Swennen, I.; Gironès, J.; Declercq, H.; Vertenten, G.; Vlaminck, L.;
Gasthuys, F.; Schacht, E.; Cornelissen, R. J Biomater Appl 2013, 27(7), 828–839.
13. Jannin, V.; Pochard, E.; Chambin, O. Int J Pharm 2006, 309(1–2), 6–15.
14. Gong, C.; Shi, S.; Dong, P.; Zheng, L.; Fu, S.; Guo, G.; Yang, J. L.; Wei, Y. Q.;
Qian, Z. Y. BMC Biotechnol 2009, 9(1), 1–13.
15. Kretlow, J. D.; Klouda, L.; Mikos, A. G. Adv Drug Delivery Rev 2007, 59(4–5),
263–273.
21571 (7 of 8)
RESEARCH ARTICLE
16. Giovagnoli, S.; Tsai, T.; DeLuca, P. AAPS PharmSciTech 2010, 11(1), 212–
220.
17. Desai, S.; Perkins, J.; Harrison, B. S.; Sankar, J. Mater Sci Eng, B 2010, 168(1–3),
127–131.
18. Herran, C. L.; Huang, Y. J Manuf Process 2012, 14(2), 98–106.
19. Cohen, D. L.; Lo, W.; Tsavaris, A.; Peng, D.; Lipson, H.; Bonassar, L. J. Tissue
Eng, Part C 2011, 17(2), 239–248.
20. Schmolka, I. R. Tissue Eng, Part C 1972, 6(6), 571–582.
21. Costa, P.; Lobo, J. M. S. J Pharm Sci 2001, 13, 123–133.
22. Ritger, P. L.; Peppas, N. A. J Controlled Release 1987, 5, 23–36.
23. Gou, M.; Li, X.; Dai, M.; Gong, C.; Wang, X.; Xie, Y.; Deng, H. X.; Chen, L. J.;
Zhao, X.; Qian, Z. Y.; Wei, Y. Q. Int J Pharm 2008, 359(1–2), 228–233.
24. Bonacucina, G.; Cespi, M.; Mencarelli, G.; Giorgioni, G.; Palmieri, G. F. Poly-
mers 2011, 3(2), 779–811.
25. Pandit, N.; Trygstad, T.; Croy, S.; Bohorquez, M.; Koch, C. J Colloid Interface
Sci 2000, 222(2), 213–220.
26. Pandit, N. K.; Kisaka, J. Int J Pharm 1996, 145(1–2), 129–136.
27. Iwanaga, S.; Saito, N.; Sanae, H.; Nakamura, M. Colloids Surf, B 2013, 109,
301–306.
28. Xuan, J.-J.; Yan, Y.-D.; Oh, D. H.; Choi, Y. K.; Yong, C. S.; Choi, H.-G. Drug Deliv
2011, 18(5), 305–311.
29. Salt, A. N.; King, E. B.; Hartsock, J. J.; Gill, R. M.; O’Leary, S. J. Hearing Res
2012, 283(1-2), 14–23.
30. King, E. B.; Salt, A. N.; Kel, G. E.; Eastwood, H. T.; O’Leary, S. J. Hearing Res
2013, 304, 159–166.
31. Salt, A. N. Otol Neurotol 2008, 29(3), 401–406.
32. Shim, J.; Seok Kang, H.; Park, W.-S.; Han, S.-H.; Kim, J.; Chang, I.-S. J Controlled
Release 2004, 97(3), 477–484.
33. Thakur, R. A.; Florek, C. A.; Kohn, J.; Michniak, B. B. Int J Pharm 2008, 364(1),
87–93.
34. Parsaee, S.; Sarbolouki, M. N.; Parnianpour, M. Int J Pharm 2002, 241(1), 185–
190.
21571 (8 of 8)
